AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31481365 — intervention group
Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 140
Study 28054939 — intervention group
Group type: EXPERIMENTAL
Intervention: trans-resveratrol
Number of subjects: 80
Study 28054939 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study 25786811 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 ml ropivacaine 0.5%
Number of subjects: 90
Study 25786811 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 ml ropivacaine 0.2%
Number of subjects: 90
Study 25786811 — intervention group
Group type: COMPARATOR
Intervention: 50 ml 0.9% saline (placebo)
Number of subjects: 90
Study 23208003 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-S
Number of subjects: 122
Study 23208003 — intervention group
Group type: COMPARATOR
Intervention: TVT-O
Number of subjects: 122
Study 21131387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 30
Study 21131387 — intervention group
Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 30
Study 19546825 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 10, 20, or 40 mg
Number of subjects: 1583
Study 19546825 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene 60 mg
Number of subjects: 1583
Study 16678642 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 10 mg QD
Number of subjects: 1093
Study 16678642 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg QD
Number of subjects: 1093
Study 16678642 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg QD
Number of subjects: 1093
Study 16678642 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg BID
Number of subjects: 1093
Study 16678642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1093
Study 15706857 — intervention group
Group type: EXPERIMENTAL
Intervention: AS and PNS
Number of subjects: 94
Study 15706857 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 94
Study 11426121 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians assessing samples containing various concentrations of blood diluted in urine for gross hematuria.
Number of subjects: 0
Study 11426121 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians' interpretations of gross hematuria.
Number of subjects: 0
Study 9250559 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg administered orally once/day for 12 days
Number of subjects: 16
Study 9250559 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered once/day for 12 days
Number of subjects: 16
Study 8318063 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg twice daily)
Number of subjects: 11
Study 8318063 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg once daily)
Number of subjects: 11
Study 8318063 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 11
Study 3554990 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg bid)
Number of subjects: 283
Study 3554990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 29720027 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enantholactam acid ester (250 mg, intramuscular injection every 2 weeks for 6 months)
Number of subjects: 24
Study 29720027 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intramuscular injection every 2 weeks for 6 months)
Number of subjects: 24
Study 29720027 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enantholactam acid ester
Number of subjects: 24
Study 29720027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 25779603 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab treatment
Number of subjects: 0
Study 25779603 — intervention group
Group type: COMPARATOR
Intervention: Baseline HAQ DI score
Number of subjects: 0
Study 24909248 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic group psychotherapy (PGP)
Number of subjects: 30
Study 24909248 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 30
Study 22393376 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg daily for 4 weeks
Number of subjects: 80
Study 22393376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 20127900 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion
Number of subjects: 156
Study 20127900 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion plus N-acetylcysteine (NAC)
Number of subjects: 156
Study 20127900 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB) infusion
Number of subjects: 156
Study 17078067 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Vim DBS activated
Number of subjects: 21
Study 17078067 — intervention group
Group type: COMPARATOR
Intervention: Bilateral Vim DBS deactivated
Number of subjects: 21
Study 15232793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca-bread (2.5% elemental calcium by weight)
Number of subjects: 53
Study 15232793 — intervention group
Group type: COMPARATOR
Intervention: Calcium acetate (control group)
Number of subjects: 53
Study 15232793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca-bread
Number of subjects: 53
Study 11716652 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent workplace health promotion program provided over 4 days and a follow-up program over 1 year
Number of subjects: 302
Study 11716652 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent workplace health promotion program
Number of subjects: 302
Study 11716652 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 302
Study 9111486 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate (42 micrograms)
Number of subjects: 11
Study 9111486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7510737 — intervention group
Group type: EXPERIMENTAL
Intervention: 220 mmol/day NaCl
Number of subjects: 16
Study 7510737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3117914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg) pre-operatively
Number of subjects: 155
Study 3117914 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine phosphate (30 mg) pre-operatively
Number of subjects: 155
Study 3117914 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ibuprofen/codeine (400 mg/30 mg) pre-operatively
Number of subjects: 155
Study 3117914 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo pre-operatively
Number of subjects: 155
Study 3117914 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ibuprofen/codeine (400 mg/30 mg) post-operatively
Number of subjects: 155
Study 3117914 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (250 mg) post-operatively
Number of subjects: 155
Study 29540293 — intervention group
Group type: EXPERIMENTAL
Intervention: G8 screening tool
Number of subjects: 0
Study 29540293 — intervention group
Group type: EXPERIMENTAL
Intervention: VES-13 screening tool
Number of subjects: 0
Study 29540293 — intervention group
Group type: EXPERIMENTAL
Intervention: mFP screening tool
Number of subjects: 0
Study 27300113 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching (10 minutes daily before bedtime for 3 weeks)
Number of subjects: 40
Study 27300113 — intervention group
Group type: COMPARATOR
Intervention: Control (waiting list)
Number of subjects: 40
Study 25491726 — intervention group
Group type: EXPERIMENTAL
Intervention: Community hospital admission (group 1)
Number of subjects: 60
Study 25491726 — intervention group
Group type: COMPARATOR
Intervention: General hospital admission (group 2)
Number of subjects: 60
Study 22800656 — intervention group
Group type: EXPERIMENTAL
Intervention: Flanker task with high calorie distractors
Number of subjects: 139
Study 22800656 — intervention group
Group type: EXPERIMENTAL
Intervention: Flanker task while hungry
Number of subjects: 139
Study 20155309 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocal Imitation Training (RIT)
Number of subjects: 21
Study 20155309 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 21
Study 18545070 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose simvastatin (80 mg/day)
Number of subjects: 31
Study 18545070 — intervention group
Group type: COMPARATOR
Intervention: Low-dose simvastatin (20 mg/day)
Number of subjects: 31
Study 15714981 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone combined with prednisone (or hydrocortisone)
Number of subjects: 0
Study 15714981 — intervention group
Group type: EXPERIMENTAL
Intervention: Estramustine and taxane
Number of subjects: 0
Study 15714981 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel-based chemotherapy
Number of subjects: 0
Study 15324531 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaprozin 1200 mg once daily
Number of subjects: 96
Study 15324531 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 50 mg three times daily
Number of subjects: 96
Study 11760378 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) therapy at a dose of 20 ppm
Number of subjects: 47
Study 11760378 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iNO therapy)
Number of subjects: 47
Study 9406362 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin administered at the time of insertion of central venous catheters
Number of subjects: 65
Study 9406362 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 65
Study 8123209 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (30 and 60 mg, PO)
Number of subjects: 0
Study 8123209 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg, PO)
Number of subjects: 0
Study 8123209 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.7 g/kg)
Number of subjects: 0
Study 8123209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8123209 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine, Verapamil, Alcohol (in combination)
Number of subjects: 0
Study 2886515 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 7
Study 2886515 — intervention group
Group type: COMPARATOR
Intervention: Control (hypoglycemia prevented)
Number of subjects: 7
Study 2886515 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 7
Study 2886515 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 7
Study 30452459 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly alkaline water (EG; n = 8)
Number of subjects: 16
Study 30452459 — intervention group
Group type: COMPARATOR
Intervention: Regular table water (CG; n = 8)
Number of subjects: 16
Study 28876476 — intervention group
Group type: EXPERIMENTAL
Intervention: School Breakfast Program participation (SBP)
Number of subjects: 404
Study 28876476 — intervention group
Group type: COMPARATOR
Intervention: Food establishment use
Number of subjects: 404
Study 24403295 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT) for 3 months
Number of subjects: 38
Study 24403295 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 38
Study 23806212 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichodermin
Number of subjects: 0
Study 21199047 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural group training (Social Competence Training for Adolescents with Borderline Intelligence)
Number of subjects: 77
Study 21199047 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 18084781 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral-medical rehabilitation approach
Number of subjects: 361
Study 18084781 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation approach
Number of subjects: 361
Study 16517365 — intervention group
Group type: EXPERIMENTAL
Intervention: Camera covers with adhesive tape sealing
Number of subjects: 90
Study 16517365 — intervention group
Group type: EXPERIMENTAL
Intervention: All tested camera covers
Number of subjects: 90
Study 16517365 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of cover with the largest diameter and arthroscope adapter
Number of subjects: 90
Study 14520164 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (DPZ), 5 to 10 mg for 30 days
Number of subjects: 23
Study 14520164 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (DPZ) for 6 months
Number of subjects: 23
Study 14520164 — intervention group
Group type: COMPARATOR
Intervention: P3 latency
Number of subjects: 23
Study 14520164 — intervention group
Group type: COMPARATOR
Intervention: CRTV
Number of subjects: 23
Study 11881701 — intervention group
Group type: EXPERIMENTAL
Intervention: Lying for 5 minutes
Number of subjects: 35
Study 11881701 — intervention group
Group type: EXPERIMENTAL
Intervention: Lying for 10 minutes
Number of subjects: 35
Study 11881701 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing for 0 minutes
Number of subjects: 35
Study 11881701 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing for 2 minutes
Number of subjects: 35
Study 9412304 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin, 400 mg twice daily, for 4 weeks
Number of subjects: 19
Study 9412304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9412304 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 19
Study 1396648 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise at 85% of Th(an,ind) (EEE)
Number of subjects: 34
Study 1396648 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise at 95% of Th(an,ind) (IEE)
Number of subjects: 34
Study 4069863 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 15 mg
Number of subjects: 14
Study 4069863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 4069863 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 5 mg
Number of subjects: 14
Study 4069863 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 10 mg
Number of subjects: 14
Study 31791389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy-oriented psychoeducation and self-managed exposure exercises delivered in four manual-based appointments with a general practitioner, along with case management by a trained health care assistant and eHealth support.
Number of subjects: 1844
Study 31791389 — intervention group
Group type: COMPARATOR
Intervention: Usual care from general practitioners.
Number of subjects: 1844
Study 31791389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy, case management, eHealth support (combined intervention).
Number of subjects: 1844
Study 28082437 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐FDG PET/CT
Number of subjects: 200
Study 28082437 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 200
Study 25546595 — intervention group
Group type: EXPERIMENTAL
Intervention: SEL program with mindfulness
Number of subjects: 99
Study 25546595 — intervention group
Group type: COMPARATOR
Intervention: Regular social responsibility program
Number of subjects: 99
Study 23989819 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimized closed circuit coronary artery bypass grafting (MCABG)
Number of subjects: 30
Study 23989819 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG (OPCAB)
Number of subjects: 30
Study 23989819 — intervention group
Group type: COMPARATOR
Intervention: Conventional CABG (CCABG)
Number of subjects: 30
Study 21790890 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal balloon ablation (TBA)
Number of subjects: 68
Study 21790890 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic supracervical hysterectomy (LSH)
Number of subjects: 68
Study 19245970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation of complex fractionated atrial electrograms (CFAEs) in Group C (n = 50)
Number of subjects: 119
Study 19245970 — intervention group
Group type: COMPARATOR
Intervention: No further ablation in Group B (n = 50)
Number of subjects: 119
Study 19245970 — intervention group
Group type: EXPERIMENTAL
Intervention: Antral pulmonary vein isolation (APVI) in Group A (n = 19)
Number of subjects: 119
Study 17086764 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilting
Number of subjects: 16
Study 17086764 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study 15536018 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril therapy for 2 months
Number of subjects: 19
Study 15536018 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 19
Study 11136273 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG) ingestion for 5 days before indometacin administration
Number of subjects: 16
Study 11136273 — intervention group
Group type: COMPARATOR
Intervention: Heat-killed LGG ingestion for 5 days before indometacin administration
Number of subjects: 16
Study 11136273 — intervention group
Group type: COMPARATOR
Intervention: Indometacin administration
Number of subjects: 16
Study 9390698 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH treatment
Number of subjects: 0
Study 9390698 — intervention group
Group type: COMPARATOR
Intervention: Low nerve growth factor levels in symptomatic infantile spasms
Number of subjects: 0
Study 9390698 — intervention group
Group type: COMPARATOR
Intervention: Normal nerve growth factor levels in cryptogenic etiology
Number of subjects: 0
Study 9390698 — intervention group
Group type: COMPARATOR
Intervention: High nerve growth factor levels in symptomatic postinfectious etiology
Number of subjects: 0
Study 8201379 — intervention group
Group type: EXPERIMENTAL
Intervention: ESHAP regimen (VP‐16 40 mg/m2/d for 4 days, methylprednisolone 500 mg IV daily for 5 days, Ara‐C 2 g/m2 IV on day 5, with cisplatin 25 mg/m2 IV for 4 days)
Number of subjects: 122
Study 8201379 — intervention group
Group type: EXPERIMENTAL
Intervention: ESHAP regimen
Number of subjects: 122
Study 3606083 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg rimantadine tablet (single dose) followed by 100 mg twice a day for 10 days (regimen 1)
Number of subjects: 24
Study 3606083 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg rimantadine tablet (single dose) followed by 100 mg once a day for 10 days (regimen 2)
Number of subjects: 24
Study 31196052 — intervention group
Group type: EXPERIMENTAL
Intervention: Fun For Wellness (FFW)
Number of subjects: 900
Study 31196052 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 900
Study 28332374 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg) with 0.2% ropivacaine (0.2 mL/kg)
Number of subjects: 60
Study 28332374 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (1 μg/kg) with 0.2% ropivacaine (0.2 mL/kg)
Number of subjects: 60
Study 28332374 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 26039935 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 μg
Number of subjects: 159
Study 26039935 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 μg with sulfonylureas
Number of subjects: 159
Study 26039935 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 μg without sulfonylureas
Number of subjects: 159
Study 23484524 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet education plus t'ai chi (TC)
Number of subjects: 26
Study 23484524 — intervention group
Group type: COMPARATOR
Intervention: Diet education
Number of subjects: 26
Study 21595527 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound generators
Number of subjects: 91
Study 21595527 — intervention group
Group type: EXPERIMENTAL
Intervention: Open ear hearing aids
Number of subjects: 91
Study 21595527 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 91
Study 20141706 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/d of lisdexamfetamine dimesylate
Number of subjects: 420
Study 20141706 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/d of lisdexamfetamine dimesylate
Number of subjects: 420
Study 20141706 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg/d of lisdexamfetamine dimesylate
Number of subjects: 420
Study 20141706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 20141706 — intervention group
Group type: EXPERIMENTAL
Intervention: All lisdexamfetamine dimesylate groups
Number of subjects: 420
Study 20141706 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate
Number of subjects: 420
Study 17107241 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (5.4 mg/day)
Number of subjects: 172
Study 17107241 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (4 mg/day)
Number of subjects: 172
Study 17107241 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (15.3 mg/day)
Number of subjects: 172
Study 17107241 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 172
Study 17107241 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 172
Study 15116860 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive approach with glycoprotein IIb/IIIa receptor blockers
Number of subjects: 0
Study 15116860 — intervention group
Group type: COMPARATOR
Intervention: Practice guidelines
Number of subjects: 0
Study 12562840 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin and Niacin (S‐N)
Number of subjects: 123
Study 12562840 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin and Niacin plus Antioxidants (S‐N+A)
Number of subjects: 123
Study 12562840 — intervention group
Group type: COMPARATOR
Intervention: Antioxidants alone
Number of subjects: 123
Study 12562840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 9474610 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetic application
Number of subjects: 50
Study 9474610 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine infusion
Number of subjects: 50
Study 9474610 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin
Number of subjects: 50
Study 8701596 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified influenza virus (N2) neuraminidase vaccine (NAV)
Number of subjects: 88